What Bendalis does

Bendalis GmbH is a privately held German specialty pharmaceutical company founded in 2006 and headquartered in Oberhaching near Munich. The company develops, manufactures, and markets a portfolio of high-quality sterile generic oncology drugs, supportive care products, and selected antibiotics for the hospital and clinical sector. Its product range spans approximately 20 active ingredients, including established chemotherapy agents (5-Fluorouracil, Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, Irinotecan, Oxaliplatin, Vinorelbine), bisphosphonates (Zoledronic acid, Ibandronic acid), Somatostatin Lyomark 3 mg, Sugammadex (acquired with worldwide distribution rights from Biofactor effective January 2025), and Vancomycin, alongside supportive care lines such as Bendafolin, the AgainLife sub-brand based on patented Adelmidrol, KapDolen, and co-distributed products Caphosol and ALOXI.

Manufacturing is conducted under GMP and GDP certification, with a production licence from the Government of Upper Bavaria and product approvals from the Federal Institute for Drugs and Medical Devices (BfArM). Manufacturing is split between Germany, via the sister company Lyomark Pharma GmbH (a contract and active ingredient manufacturer founded in 1989 and sharing dual management with Bendalis), and an additional production facility in Spain integrated into the approval system in 2026. A documented dual-sourcing strategy is used for active ingredients to ensure supply continuity.

Bendalis does not sell directly to consumers. Commercialisation occurs through a hybrid enterprise model combining direct sales engagement by an in-house scientific and sales team with exclusive and regional distribution partnerships, notably the Inceptua Group for global clinical trial supply and Inresa Arzneimittel for German hospitals. Target customers are hospitals, oncology and haematology clinics, hospital pharmacies, clinical research organisations, and pharmaceutical trial sponsors across Europe, North America, and Asia. End markets are fragmented (thousands of hospitals and 8,000+ active oncology studies served indirectly through Inceptua), and revenue is not publicly disclosed.

Name

Bendalis

Legal name

Bendalis GmbH

Website

https://bendalis.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Bendalis GmbH is a German specialty pharmaceutical company that develops, manufactures, and markets GMP-certified sterile generic oncology drugs and supportive care products for hospitals and clinical trial sponsors across Europe and international markets.

Ownership category

akta.pro rank

Product category

Specialty Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Generic oncology drugs
• Sterile pharmaceutical manufacturing
• Supportive care products
• Hospital pharmaceuticals
• Chemotherapy medications

Headquarters

HQ city

Oberhaching

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Sale of sterile oncology medicines, generic cancer drugs, supportive care products, and specialist therapeutics to hospitals, clinics, and healthcare providers. Products include 5-Fluorouracil, Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Epirubicin, Gemcitabine, Irinotecan, Octreotide, Oxaliplatin, Vinorelbine, Zoledronic acid, Ibandronic acid, Bendafolin, Sugammadex, Vancomycin, Somatostatin Lyomark 3 mg, and the AgainLife supportive care product line. Revenue is generated through direct sales and distribution partnerships globally.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Bendalis manufactures and markets a broad portfolio of generic sterile oncology chemotherapy agents (5-Fluorouracil, Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, Irinotecan, Oxaliplatin, Vinorelbine), supportive care products (Bendafolin, the AgainLife product line based on Adelmidrol, KapDolen), and specialty therapeutics (Sugammadex, Somatostatin Lyomark 3 mg, Vancomycin). Products are produced to European GMP/GDP quality standards at sterile manufacturing sites in Germany and Spain and supplied to hospitals, oncology clinics, hospital pharmacies, and clinical trial sponsors across Europe, North America and Asia.

Product overview

Bendalis is a specialty pharmaceutical company focused on the development and marketing of high-quality generic oncology drugs and supportive care products for the hospital sector. The company operates a diversified portfolio centered around three main product categories: (1) Core Oncology Products - a broad range of established generic chemotherapy agents including 5-Fluorouracil (5FU), Carboplatin, Doxorubicin, Methotrexate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, Irinotecan, Oxaliplatin, Vinorelbine, Octreotide, Zoledronic acid, Ibandronic acid, Somatostatin Lyomark 3 mg, and Sugammadex (acquired 2025); (2) Supportive Care Products including Bendafolin (folinic acid), the Again-Life sub-brand product line (OraLife, TraLife, RaLife, EvaLife, GutLife) for skin and mucous membrane protection using Adelmidrol, KapDolen for nerve fibre relief, and distributed products Caphosol (oral mucositis) and ALOXI (antiemetic); and (3) Antibiotics including Vancomycin. Products are manufactured to European quality standards with GMP and GDP certification and are distributed primarily to hospitals and clinical settings across Europe and internationally.

Differentiator

Problem solved

Functional benefit

Brands

• AgainLife: Supportive care product line including OraLife, TraLife, RaLife, EvaLife, and GutLife.

Products and services

• 5-Fluorouracil (5FU) Generic fluoropyrimidine chemotherapy medication used in the treatment of various solid tumours including colorectal, gastric, breast, and pancreatic cancers; available in 10-pack presentations.
• Carboplatin Generic platinum-based chemotherapy agent used to treat ovarian cancer, lung cancer, and other solid tumours.
• Doxorubicin Anthracycline chemotherapy medication used to treat a wide range of cancers including bladder, breast, lymphoma, and other malignancies.
• Methotrexate Antimetabolite and antifolate chemotherapy drug used in various cancers and autoimmune conditions, also used in oncology supportive care.
• Paclitaxel Taxane chemotherapy medication used to treat various solid tumours including breast, ovarian, and lung cancer.
• Docetaxel Taxane chemotherapy medication used in breast, lung, and prostate cancer; supplied via Inceptua for global clinical trial use.
• Gemcitabine Nucleoside analog chemotherapy used in pancreatic, breast, lung, ovarian, and bladder cancer; supplied via Inceptua for clinical trial use.
• Epirubicin Anthracycline chemotherapy medication used primarily in breast cancer and other solid tumours.
• Irinotecan Topoisomerase I inhibitor chemotherapy used primarily in metastatic colorectal cancer; supplied via Inceptua for clinical trial use.
• Oxaliplatin Platinum-based chemotherapy used in combination regimens for colorectal cancer; supplied via Inceptua for clinical trial use.
• Vinorelbine Vinca alkaloid chemotherapy used primarily in non-small cell lung cancer and breast cancer; supplied via Inceptua for clinical trial use.
• Octreotide Synthetic somatostatin analog used in the treatment of neuroendocrine tumours, acromegaly, and related conditions.
• Zoledronic acid Bisphosphonate used to treat bone metastases and tumour-induced hypercalcemia of malignancy.
• Ibandronic acid Bisphosphonate used in oncology-related bone metastases and osteoporosis care.
• Somatostatin Lyomark 3 mg Somatostatin analog supplied in 3 mg vials for treatment of neuroendocrine tumours, gastrointestinal bleeding, and related hospital indications.
• Sugammadex Selective relaxant binding agent used to reverse neuromuscular blockade induced by rocuronium or vecuronium during surgery; now distributed globally by Bendalis with full worldwide rights.
• Vancomycin Bendalis Glycopeptide antibiotic supplied in 500 mg and 1000 mg 10-packs for treatment of serious Gram-positive infections in hospital settings.
• Bendafolin (Folinic acid) Folinic acid (leucovorin) used as rescue therapy after high-dose methotrexate and to enhance 5-fluorouracil activity in colorectal cancer regimens.
• AgainLife Product Line (OraLife, TraLife, RaLife, EvaLife, GutLife) Medical device product line for skin and mucous membrane protection during cancer therapy, based on the patented active ingredient Adelmidrol; includes OraLife and TraLife (oral rinses/sprays), RaLife (skin cream), EvaLife (vaginal gel), and GutLife (anal cream).
• KapDolen Supportive care product for relief of damaged tissues and nerve fibres in cancer patients; available in 30 ml and 100 ml presentations.
• Caphosol Calcium phosphate oral rinse distributed by Bendalis (in partnership with EUSA Pharma) for the management of oral mucositis caused by cancer therapy.
• ALOXI (Palonosetron) Innovative 5-HT3 receptor antagonist used for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV); co-promoted by Bendalis with Riemser Arzneimittel AG in Germany.

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Biofactor GmbHcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2025Bendalis GmbH acquired the product Sugammadex completely including all global distribution rights from Biofactor GmbH effective 1 January 2025. All existing customer relationships, contractual rights, and distribution structures transferred to Bendalis, creating a single point of contact for supply, quality, and support worldwide. The acquisition marks a significant expansion of Bendalis international activities.
• Inresa Arzneimittel GmbHcoreChannel Partner/ Reseller/ Distributor · 8 December 2023Bendalis GmbH partnered with Inresa Arzneimittel GmbH as the distribution and sales partner for Somatostatin Lyomark 3 mg in Germany. Inresa was chosen as a strategic distributor to ensure continued supply of Somatostatin and maintain patient care. The product is now supplied in vials instead of ampoules, improving safety and reducing glass breakage. Inresa is established in hospitals and known for reliable on-time deliveries.
• Inceptua GroupcoreChannel Partner/ Reseller/ Distributor · 25 November 2019Bendalis entered an exclusive agreement with Inceptua Group (formerly Multipharma GmbH) for the supply of clinical trial material for generic oncology products. Inceptua became the exclusive worldwide distributor of Bendalis products for clinical trials, offering sponsors rapid access to Brexit-compliant oncology standard of care medicines manufactured within the EU. Products include Carboplatin, Docetaxel, Gemcitabine, Paclitaxel, Oxaliplatin, Vinorelbine, Irinotecan, and Fluorouracil (5FU). The partnership enables Bendalis to serve clinical trial sponsors globally through Inceptua's established network.
• Lyomark Pharma GmbHcoreStrategic or Co-development PartnerLyomark Pharma GmbH is the sister company of Bendalis, founded in 1989 in Oberhaching near Munich as a contract and active ingredient manufacturer for niche products. Lyomark provides lyophilised and liquid sterile product manufacturing services to Bendalis. Services include dossier provision, maintenance, and submission of national and international approvals for pharmaceutical companies. The companies share management (Dr. Wolfgang Burger and Dr. Dirk Hütten serve as Managing Directors of both entities).
• EUSA Pharma GmbHminorChannel Partner/ Reseller/ DistributorIn 2008, Bendalis entered a collaboration with EUSA Pharma GmbH for the distribution of Caphosol for the treatment of oral mucositis, a supportive care product for cancer patients.
• Riemser Arzneimittel AGminorGTM or Marketing PartnerFrom the beginning of 2011, Bendalis had a co-promotion agreement with Riemser Arzneimittel AG for Aloxi (Palonosetron), an innovative 5-HT3 receptor antagonist for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV). This partnership was for the German market.
• European, North American and Asian Strategic PartnersminorStrategic or Co-development PartnerBendalis has strategic alliances with partners in Europe, North America and Asia to continuously expand global reach. These partnerships focus on collaborative innovation to drive new therapies and standards in oncology. The company is seeking additional partners who share their values to advance oncology therapeutics.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bendalis-gmbh

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bendalis